External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EASL ILC 2023
Roche and Genentech at

EASL ILC 2023

June 21 - June 24
Vienna, Austria
easlcongress.eu
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
10:30 AM
Duration 12mins Vienna, Austria
Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
Ahmed Kaseb, Minshan Chen, Pierce Chow, Masatoshi Kudo, Han Chu Lee, Adam Yopp, Lars Becker, Sairy Hernandez, Bruno Kovic, Qinshu Lian, Ning Ma, Chun Wu, Shukui Qin, Ann-Lii Cheng
Oncology | Gastrointestinal Cancer - Hepatocellular Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.